Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?
作者信息
Blower P, Aapro M
出版信息
Br J Cancer. 2002 May 20;86(10):1662-3; author reply 1664. doi: 10.1038/sj.bjc.6600313.
Abstract
(2002) , 1662–1663. DOI: 10.1038/sj/bjc/6600313 www.bjcancer.com © 2002 Cancer Research UK
摘要
相似文献
1
Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?
Br J Cancer. 2002 May 20;86(10):1662-3; author reply 1664. doi: 10.1038/sj.bjc.6600313.
2
Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials.
Cancer. 2000 Dec 1;89(11):2301-8. doi: 10.1002/1097-0142(20001201)89:11<2301::aid-cncr19>3.0.co;2-6.
3
5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
Drugs. 1998 Feb;55(2):173-89. doi: 10.2165/00003495-199855020-00002.
4
Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
Oncol Rep. 1998 Jan-Feb;5(1):273-80. doi: 10.3892/or.5.1.273.
5
Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
J Chemother. 1996 Jun;8(3):237-42. doi: 10.1179/joc.1996.8.3.237.
6
Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis.
Am J Health Syst Pharm. 2000 Sep 15;57(18):1685-97. doi: 10.1093/ajhp/57.18.1685.
7
Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin.
J Chemother. 2000 Feb;12(1):105-8. doi: 10.1179/joc.2000.12.1.105.
8
[Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers].
Anasthesiol Intensivmed Notfallmed Schmerzther. 1996 May;31(4):200-4. doi: 10.1055/s-2007-995902.
9
'... setron': are 5-HT3 receptor antagonists different?
Eur J Cancer. 1993;29A(12):1655. doi: 10.1016/0959-8049(93)90097-y.
10
Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.
Am J Clin Oncol. 2000 Apr;23(2):185-91. doi: 10.1097/00000421-200004000-00016.
引用本文的文献
1
Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?
CNS Drugs. 2005;19(3):225-38. doi: 10.2165/00023210-200519030-00004.
本文引用的文献
1
Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy.
Br J Cancer. 2001 Oct 19;85(8):1099-101. doi: 10.1054/bjoc.2001.2045.
2
Efficacy of ondansentron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study.
J Exp Clin Cancer Res. 2001 Mar;20(1):29-34.
3
Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy.
Clin J Oncol Nurs. 1999 Jul;3(3):113-9.
4
Use of granisetron in patients refractory to previous treatment with antiemetics.
Anticancer Drugs. 1998 Jun;9(5):381-5. doi: 10.1097/00001813-199806000-00002.
5
Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration.
Support Care Cancer. 1998 May;6(3):237-43. doi: 10.1007/s005200050160.
6
Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group.
Eur J Cancer. 1996 Aug;32A(9):1523-9. doi: 10.1016/0959-8049(96)00132-3.
7
BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors.
Neuropharmacology. 1993 Aug;32(8):729-35. doi: 10.1016/0028-3908(93)90180-b.
8
A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group.
J Cancer Res Clin Oncol. 1993;119(6):350-4. doi: 10.1007/BF01208844.
9
A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group.
Support Care Cancer. 1994 May;2(3):177-83. doi: 10.1007/BF00417477.
10
Ondansetron clinical pharmacokinetics.
Clin Pharmacokinet. 1995 Aug;29(2):95-109. doi: 10.2165/00003088-199529020-00004.
Zotero 插件